Manteio Capital’s Standard BioTools LAB Stock Holding History

Manteio Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-26,213	Closed	-$103K	–	112
2021 Q4	$103K	Buy	+26,213	New	+$123K	0.13%	219

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Manteio Capital's LAB Position: Q1 2022 in Review

Manteio Capital sold out of Standard BioTools (LAB) in Q1 2022, closing a stake of 26,213 shares — an estimated $103K sold.

Manteio Capital first reported a position in LAB in Q4 2021 and held it in 1 quarter. The position peaked at $103K in Q4 2021. 109 funds tracked by Wall St. Rank hold LAB as of Q1 2022.

Manteio Capital reported no remaining Standard BioTools position as of Q1 2022 after selling out during the quarter.
Manteio Capital sold 26,213 Standard BioTools shares in Q1 2022, an estimated $103K.
Manteio Capital first reported a position in Standard BioTools in Q4 2021 and held it in 1 quarter.
Manteio Capital's Standard BioTools position peaked at $103K in Q4 2021.
109 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2022.

Based on Manteio Capital's 13F filing for Q1 2022.